Publications by authors named "B Kisacik"

Objective: To evaluate the development of anti-drug antibodies (ADAb) against tumor necrosis factor inhibitors (TNFi) therapy during a 2-year period and search the factors linked to patients with axial spondyloarthritis (axSpA).

Methods: Biologic-naive patients with axSpA were included in this observational study. Serum drug levels and ADAb were measured at weeks 12, 24, 52, and 104 of treatment by enzyme-linked immunosorbent assay (ELISA).

View Article and Find Full Text PDF

: Secukinumab is a monoclonal antibody against interleukin 17 approved for patients with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis. Treating axSpA and PsA patients with a history of malignancy is a challenge. While initial results on the applicability of secukinumab in this patient group are positive, the number of studies on this topic remains limited.

View Article and Find Full Text PDF
Article Synopsis
  • Inflammatory low back pain (IBP) is commonly associated with spondylarthritis (SpA) but can also be a symptom of various malignancies, both hematologic and solid tumors.
  • A study analyzed 34 patients diagnosed with malignancy-related IBP over the past decade, comparing their clinical features to a control group of patients with axial SpA.
  • Findings revealed that malignancy-related IBP patients had higher levels of inflammatory markers and a similar ratio of hematologic to solid tumors, suggesting that malignancies should be considered in differential diagnoses of IBP.
View Article and Find Full Text PDF

Objective: In this study, our objective was to present real-life data on the incidence of inflammatory bowel disease (IBD) among patients receiving secukinumab treatment.

Methods: The study consisted of 209 patients who had prior exposure to anti-tumor necrosis factor (TNF) or were biologically naive. Patients with a pre-existing history of IBD were excluded from the study.

View Article and Find Full Text PDF
Article Synopsis
  • * Researchers analyzed data from 330 patients diagnosed with GCA, finding that 18.8% experienced relapses during a follow-up period, and only 23.8% were able to stop GC treatment entirely.
  • * The study highlighted that a significant portion of patients (66.2%) had at least one indication of damage due to vasculitis, and there were also considerable side effects related to GC treatment.
View Article and Find Full Text PDF